Connect with us

Politics

Bill To Legalize Hemp Passes Key Senate Committee

Published

on

A wide-ranging agricultural bill that includes a provision to legalize hemp made its way through a crucial Senate committee on Wednesday, passing 20-1.

Last week, Senate Majority Leader Mitch McConnell (R-KY) inserted the cannabis provisions—which would remove hemp from the federal definition of marijuana and also free up hemp cultivators to receive federal crop insurance—into the 2018 Farm Bill. The move builds upon the senator’s successful effort to include protections for industrial hemp research programs against federal interference in the 2014 version of the bill.

“I think it’s time we took this step,” McConnell said before the Senate Committee on Agriculture, Nutrition and Forestry on Wednesday. “I think everybody has now figured it out that this is not the other plant,” he added, referring to hemp’s cannabis cousin, marijuana.

“All the people in rural Kentucky who grew up with tobacco are hoping that this will be really something. And as we all know, hemp is very diversified. It can end up in your car dashboard, it can end up in food, it can end up in certain kinds of pharmaceuticals. It’s time to figure it out and see where the market will take us. I think it’s an important new development in American agriculture.”

McConnell also appeared on the Senate floor earlier Wednesday to reaffirm his support for the bill’s hemp provision.

“It’s a landmark piece of legislation that will benefit farmers and communities throughout our country,” McConnell said. “I’m particularly excited that the legislation being considered today includes provisions from the Hemp Farming Act of 2018…which I introduced earlier this year.”

“This will empower farmers in Kentucky and other states to fully realize the potential of industrial hemp.”

Late on Tuesday, Sen. Chuck Grassley (R-IA) filed an amendment to the Farm Bill that would require the Justice Department to “modify the definition of the term ‘hemp’ and make a determination as to whether cannabidiol [CBD] should be a controlled substance” under federal law.

Hemp legalization advocates swiftly responded, urging committee members to oppose the proposed changes, which they feared would gut the intent of McConnell’s legislation.

Kentucky’s Commissioner of Agriculture also tweeted that “I STRONGLY oppose Senator Grassley’s Amendment.”

Grassley spoke in defense of his proposed amendment, lamenting that he’d “objected on procedural grounds” to the hemp legalization provision and was ignored. He also argued that he’d support the legalization of industrial hemp, but not its derivatives such as CBD. Grassley voiced concerns that the bill would “allow any snake oil salesman” to peddle unregulated CBD products to patients suffering from conditions such as epilepsy and anxiety.

Grassley also claimed that the hemp legalization provision falls “squarely within the Judiciary Committee’s jurisdiction,” which he chairs, as opposed to the Senate Committee On Agriculture.

Notably, however, he didn’t call for a committee vote on his proposed amendment. Instead, he asked that members “work with me to modify this provision after this bill gets out of committee.”

McConnell pushed back against the senator’s remarks. He said that he felt confident in the integrity of the bill and the safeguards it provides after consulting with the Justice Department, the Food and Drug Administration (FDA) and the ranking member of the Senate Committee on the Judiciary. Grassley’s amendment would “undercut essential premise of the bill, namely that help and its derivatives should be a legal agricultural commodity,” McConnell said.

“Hemp should be allowed to flourish again in this county…”

During the Wednesday committee markup, several lawmakers voiced support for legalizing hemp, including Sens. Michael Bennet, (D-CO), Heidi Heitkamp (D-ND) and Amy Klobuchar (D-MN).

Though the bill could still be subject to further amendments when it reaches the Senate floor, it’s doubtful that the hemp provisions would face significant resistance given their sizable bipartisan support. McConnell is joined by Senate Minority Leader Chuck Schumer (D-NY) and Sen. Ron Wyden (D-OR), among others, who also favor of the provision.

McConnell also said he received assurances from U.S. Attorney General Jeff Sessions, a staunch marijuana prohibitionist, that while he wouldn’t embrace the hemp legalization move, he “is not going to oppose us,” the Associated Press reported.

Lawmakers argue that federal laws pertaining to hemp cultivation have done a disservice to farmers and businesses in the United States. While it’s legal to sell hemp products, such as clothing and cosmetics, it remains illegal to cultivate the non-psychoactive cousin of marijuana under federal law.

Wyden took to the Senate floor last week, accompanied by two baskets full of hemp products, to make just that point.

“There can’t be many policies on the books that are more anti-farmer than that one,” he said. “Hemp growers in places like Canada and China must just be laughing all the way to the bank. They’re cashing in, while our farmers have their hands tied by the current hemp restrictions.”

And in a statement provided to Marijuana Moment on Wednesday, Wyden said that [l]ifting the nonsensical ban on growing hemp in Oregon and nationwide reverses decades of policymaking that hurt farmers’ ability to innovate and grow jobs here at home.”

“Our bipartisan legislation will help farmers unlock the full economic potential of industrial hemp, spurring economic growth and creating good-paying red, white, and blue jobs in rural communities across the country. Passing the Hemp Farming Act through the Senate Agriculture Committee marks a huge step toward allowing consumers to buy products made with hemp grown in America.”

“It’s a crock,” Schumer, the Democratic leader, said last month, of the nation’s ban on hemp. “It makes no sense that the [Drug Enforcement Administration] is the primary regulator, and that they stop farmers and investors from growing hemp. Why are we buying hemp from other countries, when we have hundreds of acres that could be grown right here in our backyard?”

In a related move, for the third year in a row, the Senate unanimously adopted a resolution last week that acknowledged “the growing economic potential of industrial hemp.” But with the 2018 Farm Bill, this could represent the first year that a hemp legalization provision actually passes in the Senate.

All of this hemp momentum comes as many lawmakers are vying for broader cannabis reform measures, including the newly filed STATES Act, which would exempt marijuana from the Controlled Substances Act for states where the plant has been legalized. It would also provide protections for banks dealing with legal cannabis businesses and legalize industrial hemp.

President Donald Trump told reporters that he “probably will end up supporting that [bill],” last week.

Attempts to include hemp-related amendments to the House version of the Farm Bill were blocked last month. That said, the Senate leader is in a good position to push the legislation forward through a bicameral conference committee, which will eventually craft a final bill to send to the president’s desk.

McConnell said a full Senate vote on the bill would take place before July 4.

See below for a summary of the Farm Bill’s hemp provisions, as prepared by the Agriculture Committee:

Sec. 7125 Supplemental and Alternative Crops; Hemp
x Reauthorizes a research project for supplemental and alternative crops including canola and hemp.

Sec. 7401 Critical Agricultural Materials Act
x Reauthorizes the Critical Agricultural Materials Act, and includes hemp as an eligible product.

Sec. 7415 Legitimacy of Industrial Hemp Research
x Requires the Secretary to conduct a study and report on the economic viability of the domestic production and sale of industrial hemp.

Sec. 10111 Hemp Production
x Amends the Agricultural Marketing Act of 1946 to allow states to regulate hemp growth and production, based on a state or tribal plan that includes information on locations of hemp production, testing for THC concentration, disposal of plants that are out of compliance, and negligence or other violations of the state or tribal plan.
x Requires states and tribes without USDA approved plans to follow federal laws and regulations promulgated by USDA on hemp production.

Sec. 10112 Rule of Construction
x Clarifies that nothing in this title authorizes interference with the interstate commerce of hemp.

Sec. 11101 Definitions
x Defines cover crop termination and defines hemp as used in section 297A of the Agricultural Marketing Act of 1946.

Sec. 11106 Insurance period
x Amends section 508(a)(2) of the Federal Crop Insurance Act by adding hemp.

Sec. 11112 Submission of policies and materials to board.
x Amends section 508(h) of the Federal Crop Insurance Act to allow the Corporation to waive the viability and marketability requirement in the case of a policy or pilot program relating to the production of hemp.

Sec. 11120 Agricultural commodity
x Amends section 518 of the Federal Crop Insurance Act by adding hemp.

Sec. 11121 Reimbursement of research, development, and maintenance costs
x Amends section 522(b) of the Federal Crop Insurance Act to allow the Board and Corporation to waive the viability and marketability requirements in the case of research and development relating to a policy to insure the production of hemp.

UPDATE June 13, 2018 8:38am PT: This story has been updated to include new comments from Sens. Grassley and McConnell.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Kyle Jaeger is Marijuana Moment's Sacramento-based senior editor. His work has also appeared in High Times, VICE and attn.

Politics

Virginia Has Sealed 64,000 Marijuana Distribution Charges Since Legalization Took Effect This Summer

Published

on

“These aren’t just numbers and there are families attached.”

By Ned Oliver, Virginia Mercury

Virginia has sealed records documenting more than 64,000 misdemeanor marijuana distribution charges since the state legalized the drug in July.

The figure came out Thursday during a meeting of the legislature’s Cannabis Oversight Commission.

Officials said the records were scrubbed from the state’s criminal record database, which is used by employers like school boards, state agencies and local governments to screen employees.

The state had already sealed 333,000 records detailing charges of simple possession last year after the state reduced the offense to a civil infraction on par with a traffic offense, said Shawn G. Talmadge, the Deputy Secretary of Public Safety and Homeland Security.

Lawmakers directed the state to expand that effort when they voted to broadly legalize recreational use of marijuana earlier this year.

The legislature also agreed to a broader expungement reform that will automatically seal other misdemeanor charges, including underage possession of alcohol, use of a fake ID, petit larceny, trespassing and disorderly conduct. Talmadge said those charges will remain in the system until the state finishes updating the software it uses to track criminal records.

“As of right now, the process is proceeding,” he said.

Members of the oversight commission also heard from two advocates who urged them to move fast to address people currently imprisoned for marijuana offenses—a category of people the legalization legislation passed this year did not address.

Chelsea Higgs Wise, the leader of the advocacy group Marijuana Justice, and Gracie Burger, with the Last Prisoner Project, said Department of Corrections data suggests there are currently 10 people being held solely on serious marijuana charges.

They said it remains unknown how many more are being held because of marijuana related probation violations.

“These aren’t just numbers and there are families attached,” Burger said.

This story was first published by Virginia Mercury,

Nevada Sold More Than $1 Billion In Marijuana In One Year, Officials Report

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

DEA Proposes Dramatic Increase In Marijuana And Psychedelic Production In 2022, Calling For 6,300 Percent More MDMA Alone

Published

on

The Drug Enforcement Administration (DEA) is proposing a dramatic increase in the legal production of marijuana and psychedelics like psilocybin, LSD, MDMA and DMT to be used in research next year.

In a notice scheduled to be published in the Federal Register on Monday, the agency said there’s been a “significant increase in the use of schedule I hallucinogenic controlled substances for research and clinical trial purposes,” and it wants authorized manufacturers to meet that growing demand.

DEA had already massively upped its proposed 2021 quota for cannabis and psilocybin last month, but now it’s calling for significantly larger quantities of research-grade marijuana and a broader array of psychedelics to be manufactured in 2022.

It wants to double the amount of marijuana extracts, psilocybin and psilocyn, quadruple mescaline and quintuple DMT. What especially stands out in the notice is MDMA. The agency is proposing an enormous 6,300 percent boost in the production of that drug—from just 50 grams in 2021 to 3,200 grams in the coming year—as research into its therapeutic potential continues to expand.

LSD would see a 1,150 percent increase, up to 500 grams of the potent psychedelic.

Marijuana itself would get a 60 percent boost under DEA’s proposal, up to 3.2 million grams in 2022 from the 2 million grams last year.

Here’s a visualization of the proposed quota increase from 2021 to 2022 for marijuana and cannabis extracts:

For all other THC, psilocybin, psilocyn and MDMA:

And for other psychedelic substances like LSD, mescaline and DMT:

DEA said in the Federal Register notice that it has been receiving and approving additional applications to “grow, synthesize, extract, and manufacture dosage forms containing specific schedule I hallucinogenic substances for clinical trial purposes” to achieve these ambitious quotas.

“DEA supports regulated research with schedule I controlled substances, as evidenced by increases proposed for 2022 as compared with aggregate production quotas for these substances in 2021,” the agency said, adding that it working “diligently” to process and approve marijuana manufacturers applications in particular, as there’s currently only one farm at the University of Mississippi that’s permitted to cultivate the plant for research.

“Based on the increase in research and clinical trial applications, DEA has proposed increases in 3,4- Methylenedioxyamphetamine (MDA), 3,4-Methylenedioxymethamphetamine (MDMA), 5-Methoxy-N,N-dimethyltryptamine, Dimethyltryptamine, Lysergic acid diethylamide (LSD), Marihuana, Marihuana Extract, Mescaline, Psilocybin, Psilocyn, and All Other Tetrahydrocannabinols to support manufacturing activities related to the increased level of research and clinical trials with these schedule I controlled substances.”

Here are the exact numbers for the proposed 2021 and 2022 quotas:

Substance 2021
2022 proposed
Marijuana 2,000,000 3,200,000
Marijuana extract 500,000 1,000,000
All other tetrahydrocannabinol 1,000 2,000
Psilocybin 1,500 3,000
Psilocyn 1,000 2,000
MDMA 50 3,200
LSD 40 500
Mescaline 25 100
DMT 50 250
5-MeO-DMT 35 550
MDA 55 200

A 30-day public comment period will be open after the notice is formally published on Monday.

It’s difficult to overstate just how significant the proposed 2022 increases are, but it’s certainly true that scientific and public interest in marijuana and psychedelics has rapidly increased, with early clinical trials signaling that such substances show significant therapeutic potential.

National Institute on Drug Abuse (NIDA) Director Nora Volkow told Marijuana Moment in a recent interview that she was encouraged by DEA’s previous proposed increase in drug production quota. She also said that studies demonstrating the therapeutic benefits of psychedelics could be leading more people to experiment with substances like psilocybin.

Advocates and experts remain frustrated that these plants and fungi remain in the strictest federal drug category in the first place, especially considering the existing research that shows their medical value for certain conditions.

A federal appeals court in August dismissed a petition to require the DEA to reevaluate cannabis’s scheduling under the Controlled Substances Act. However, one judge did say in a concurring opinion that the agency may soon be forced to consider a policy change anyway based on a misinterpretation of the therapeutic value of marijuana.

Separately, the Washington State attorney general’s office and lawyers representing cancer patients recently urged a federal appeals panel to push for a DEA policy change to allow people in end-of-life care to access psilocybin under state and federal right-to-try laws.

Singer Melissa Etheridge And Activist Van Jones Promote Psychedelics Reform As Movement Grows

Image element courtesy of Kristie Gianopulos.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Supreme Court Won’t Hear Case On Legalizing Safe Drug Consumption Sites, But Activists Are Undeterred

Published

on

The U.S. Supreme Court (SCOTUS) has rejected a request to hear a case on the legality of establishing safe injection sites where people can use illicit drugs in a medically supervised environment.

The justices announced on Tuesday that they decided against taking up the case raised by the nonprofit Safehouse, despite the pleas of attorneys general from 10 states and D.C. who recently filed amici briefs urging the court’s involvement.

Representatives from 14 cities and counties, as well as the mayor of Philadelphia, which is at the center of the current case, also filed briefs in support of the case in recent days.

Safehouse was set to launch a safe consumption site in Philadelphia before being blocked by a legal challenge from the Trump administration. It filed a petition with the nation’s highest court in August to hear the case.

But while the Supreme Court declined to take action—and the Biden administration passed up its voluntary opportunity to weigh in at this stage, which may well have influenced the justices’ decision—activists say the battle will continue at a lower federal court level, where the administration will have to file briefs revealing its position on the issue.

“We were disappointed that the government chose not to respond to our petition,” Safehouse Vice President Ronda Goldfein told Filter. “They said, ‘We’re going to waive our right to respond,’ [and] the Supreme Court declined to review our case. Ordinarily that sounds like the end of the road—but in our case we are still pursuing our claims in a different venue.”

That venue will be the the federal district court in Philadelphia, where activists plan to submit multiple arguments related to religious freedom and interstate commerce protections. The Biden administration will be compelled to file a response in that court by November 5.

“If they don’t respond, they lose,” Goldfein said.

A coalition of 80 current and former prosecutors and law enforcement officials—including one who is President Joe Biden’s pick for U.S. attorney of Massachusetts—previously filed a brief urging the Supreme Court to take up Safehouse’s safe injection case.

Fair and Justice Prosecution, the group that coordinated the amicus brief, also organized a tour of Portugal for 20 top prosecutors in 2019 so they could learn about the successful implementation of the country’s drug decriminalization law.

If the Supreme Court were to have taken the case and rule in favor of Safehouse, it could have emboldened advocates and lawmakers across the country to pursue the harm reduction policy.

The governor of Rhode Island signed a bill in July to establish a safe consumption site pilot program where people could test and use currently illicit drugs in a medically supervised environment. It became the first state in the country to legalize the harm reduction centers. It’s not clear whether the Department of Justice will seek to intervene to prevent the opening of such facilities in that state.

Massachusetts lawmakers advanced similar legislation last year, but it was not ultimately enacted.

A similar harm reduction bill in California, sponsored by Sen. Scott Wiener (D), was approved in the state Senate in April, but further action has been delayed until 2022.

Florida Democratic Candidates For Governor Fight Over Who Supports Marijuana Reform The Most

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Marijuana Moment